These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12095703)

  • 1. Identification of a novel HLA-B-35-restricted cytotoxic T-lymphocyte epitope within human immunodeficiency type 1 (HIV-1) P17(Gag).
    M'Bika JP; Achour A
    Immunol Lett; 2002 Oct; 83(3):149-50. PubMed ID: 12095703
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.
    Masemola AM; Mashishi TN; Khoury G; Bredell H; Paximadis M; Mathebula T; Barkhan D; Puren A; Vardas E; Colvin M; Zijenah L; Katzenstein D; Musonda R; Allen S; Kumwenda N; Taha T; Gray G; McIntyre J; Karim SA; Sheppard HW; Gray CM;
    J Immunol; 2004 Oct; 173(7):4607-17. PubMed ID: 15383595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.
    Brander C; Yang OO; Jones NG; Lee Y; Goulder P; Johnson RP; Trocha A; Colbert D; Hay C; Buchbinder S; Bergmann CC; Zweerink HJ; Wolinsky S; Blattner WA; Kalams SA; Walker BD
    J Virol; 1999 Dec; 73(12):10191-8. PubMed ID: 10559335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.
    Dorrell L; Willcox BE; Jones EY; Gillespie G; Njai H; Sabally S; Jaye A; DeGleria K; Rostron T; Lepin E; McMichael A; Whittle H; Rowland-Jones S
    Eur J Immunol; 2001 Jun; 31(6):1747-56. PubMed ID: 11385619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.
    Cohen WM; Bianco A; Connan F; Camoin L; Dalod M; Lauvau G; Ferriès E; Culmann-Penciolelli B; van Endert PM; Briand JP; Choppin J; Guillet JG
    J Virol; 2002 Oct; 76(20):10219-25. PubMed ID: 12239297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
    Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
    Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.
    Yokomaku Y; Miura H; Tomiyama H; Kawana-Tachikawa A; Takiguchi M; Kojima A; Nagai Y; Iwamoto A; Matsuda Z; Ariyoshi K
    J Virol; 2004 Feb; 78(3):1324-32. PubMed ID: 14722287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
    Gray CM; Lawrence J; Schapiro JM; Altman JD; Winters MA; Crompton M; Loi M; Kundu SK; Davis MM; Merigan TC
    J Immunol; 1999 Feb; 162(3):1780-8. PubMed ID: 9973442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais.
    Bond KB; Sriwanthana B; Hodge TW; De Groot AS; Mastro TD; Young NL; Promadej N; Altman JD; Limpakarnjanarat K; McNicholl JM
    AIDS Res Hum Retroviruses; 2001 May; 17(8):703-17. PubMed ID: 11429111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.
    Currier JR; deSouza M; Chanbancherd P; Bernstein W; Birx DL; Cox JH
    J Virol; 2002 May; 76(10):4971-86. PubMed ID: 11967314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of HLA-A*3303-restricted, HIV type 1 Pol- and Gag-derived cytotoxic T cell epitopes.
    Hossain MS; Tomiyama H; Inagawa T; Ida S; Oka S; Takiguchi M
    AIDS Res Hum Retroviruses; 2003 Jun; 19(6):503-10. PubMed ID: 12882660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
    Borghan MA; Oka S; Takiguchi M
    Tissue Antigens; 2005 Oct; 66(4):305-13. PubMed ID: 16185326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope.
    Kan-Mitchell J; Bisikirska B; Wong-Staal F; Schaubert KL; Bajcz M; Bereta M
    J Immunol; 2004 May; 172(9):5249-61. PubMed ID: 15100263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.
    Klein MR; van der Burg SH; Hovenkamp E; Holwerda AM; Drijfhout JW; Melief CJ; Miedema F
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2191-201. PubMed ID: 9747728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
    Ferrari G; Neal W; Ottinger J; Jones AM; Edwards BH; Goepfert P; Betts MR; Koup RA; Buchbinder S; McElrath MJ; Tartaglia J; Weinhold KJ
    J Immunol; 2004 Aug; 173(3):2126-33. PubMed ID: 15265949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.
    Goulder PJ; Tang Y; Pelton SI; Walker BD
    J Virol; 2000 Jun; 74(11):5291-9. PubMed ID: 10799606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides.
    Sewell AK; Harcourt GC; Goulder PJ; Price DA; Phillips RE
    Eur J Immunol; 1997 Sep; 27(9):2323-9. PubMed ID: 9341776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsynonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules.
    Birk M; Vahlne A; Sönnerborg A; Sällberg M
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):241-8. PubMed ID: 9491914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
    J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.
    Allen TM; Altfeld M; Yu XG; O'Sullivan KM; Lichterfeld M; Le Gall S; John M; Mothe BR; Lee PK; Kalife ET; Cohen DE; Freedberg KA; Strick DA; Johnston MN; Sette A; Rosenberg ES; Mallal SA; Goulder PJ; Brander C; Walker BD
    J Virol; 2004 Jul; 78(13):7069-78. PubMed ID: 15194783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.